You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The precision medicine company also is accelerating its push into diabetes, depression, and cardiology after getting its solid-tumor test turnaround down to 9 days.
Now valued at $5 billion, the company will apply the new funding to continue its expansion in diabetes, depression, and cardiology.
Aiming to improve patient access to critical drugs and tests, a group of legislators have started a caucus to shore up bipartisan support for personalized medicine.
Paired tumor/germline analysis is not routinely done in cancer care, but some labs are starting to report incidental germline findings alongside patient's tumor profiles.
Tempus said that Akesogen's lab provides a range of testing services, including for inherited risk of cancer, microbiome profiling, whole-genome genotyping, and more.
Tempus Labs researchers said they could match more than 40 percent of patients to a targeted treatment and 77 percent of patients to a relevant clinical trial.
Industry experts say a receptive market and investor interest in new technologies have spurred the increase in genomics tools and molecular diagnostics IPOs.
Tempus is eligible for milestone payments and royalties for any oncology therapeutics Genmab might develop based on their joint research projects.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.